Navigation Links
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
Date:6/28/2008

MOUNTAIN VIEW, Calif., June 28 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (IV) DHE. The study results were among six posters relating to the MAP0004 program that the Company presented at the American Headache Society 50th Annual Scientific Meeting in Boston, MA.

In this receptor pharmacology study, MAP0004 stimulated receptors that relieve migraine at levels comparable to IV DHE, but did not activate receptors associated with side effects frequently seen with IV DHE. In addition, MAP0004 did not affect receptors that have a role in regulating pulmonary function.

"The selective binding of MAP0004 at receptors associated with migraine rather than those associated with side effects offers a mechanistic hypothesis for the favorable safety and efficacy profile of MAP0004 compared to IV DHE that we have observed in our initial clinical studies," said Thomas A. Armer, Ph.D., Chief Scientific Officer of MAP Pharmaceuticals. "The absence of negative effects of MAP0004 on pulmonary function in asthmatic subjects observed in a Phase 2 study is also important because migraine and asthma are frequently co-morbid conditions."

MAP0004 is designed to be self-administered by patients at home via MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In Phase 2 studies with migraneurs and with asthmatics, treatment with MAP0004 was well-tolerated, with no serious adverse events reported. Drug-induced nausea was very low and migraine-associated nausea also decreased with treatment.

The Company presented a poster summariz
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
6. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
7. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
8. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... /PRNewswire-iReach/ -- Gateway Analytical announced today that they ... Annual Global Pharma Manufacturing Summit in ... The Global Pharma Manufacturing Summit offers a networking ... biologic pharmaceutical manufacturing. The conference is focused on ... such as the increasing pressure to grow and ...
(Date:8/28/2014)... Orthopaedics, the Official Joint Replacement Products of the PGA TOUR ... to golf fans at the next stop of the FedEx ... company,s fan destination – "The Stryker Mobility Zone" – will ... TPC Boston in Norton, MA starting ... the Deutsche Bank Championship, Stryker will be providing golf fans ...
(Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... ADHD Therapeutics to 2020 - Broadened ... to Drive Market Growth despite Patent ... ADHD Therapeutics to ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 4Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8
(Date:8/28/2014)... Blood's Thicker Than Water is based on ... ties in the heart of the city. Raymond E. Blake ... about how disrespect caused two families to collide with each ... The Yayo Boyz and the M.O.B. Boyz clash in a ... onlookers in a silent terror. "Guerrilla," AKA "Real," runs his ...
(Date:8/28/2014)... Millennium Treatment Group recently announced a new goal. ... Treatment Group is working to close it, providing more people ... to the National Survey on Drug Use and Health ... benefited from treatment for drug and/or substance abuse, but only ... there is a large treatment gap in the United States. ...
(Date:8/28/2014)... 28, 2014 Millennium Treatment Group has ... in the workplace. A recent report from the ... states that drug abuse is costing employers an estimated ... are addicted to drugs affect their employers and the ... into the workplace, causing expensive problems for their employers, ...
(Date:8/28/2014)... News) -- Arguments between parents may damage their relationships ... in more than 200 families were asked to make ... of each day, mothers and fathers rated the quality ... On days when parents reported conflict and tension ... also strained, according to the study recently published in ...
(Date:8/28/2014)... LEBANON, NH As the federal government plans its exit ... it to rethink its role in providing health care to ... Journal of Medicine . , "To simply go on doing ... challenge that the Veterans Health Administration,s cost and population structure ... Dartmouth Institute for Health Policy & Clinical Practice, and David ...
Breaking Medicine News(10 mins):Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:A VA exit strategy 2
... in Head Start programs have discovered that those from ... at higher risk for being overweight. ,The ... found that Mexican children “were almost twice as likely ... of ethnic groups, including non-Mexican Hispanic children.” ...
... diabetes, lupus and rheumatoid arthritis are autoimmune diseases, which ... system// to check itself. ,Researchers are still ... are responsible for weakening the immune system. Now, a ... Dana-Farber Cancer Institute have discovered a crucial group of ...
... diet is said to have a beneficial effect on the health ... in men are the following // ,Vegetables like tomatoes, carrot, ... the non-vegetarian food like oysters, shrimps and deep sea fish has ... digestion of proteins and nutrients and also help in secretion of ...
... color”, says Dr.Clive Anderson, consultant dermatologist and venereologist at ... part of a move to get Jamaicans aware of ... island’s youth resort to bleaching or lightening the skin ... ,Government health officials plan to launch a campaign against ...
... Microbiology Laboratory of Canada is involved in developing a vaccine for ... //to benefit the community of apes who are in the process ... ,According to Steven Jones who is leading this research, the Ebola ... population. This virus is said to be contacted from a specific ...
... American Heart Journal recently reported a study which states that ... lean men. //This research was conducted by a team of ... this study, when obese men were hospitalized with heart attacks, ... is said to be due to the presence of fat ...
Cached Medicine News:Health News:Head Start Kids in ESL Families More Prone to Obesity 2Health News:Understanding Autoimmune Disease 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: